research Madarosis, Milphosis, Eyelash Trichomegaly, and Dermatochalasis: Conditions Affecting the Periocular Area
The document concludes that changes in eyelashes and eyelid skin can indicate various local and systemic diseases.
Search
for
Sort by
Research
480-510 / 1000+ results 
research Cetuximab-Associated Elongation of the Eyelashes
Cetuximab can cause eyelash growth, which is rare but manageable.
research Unexpected Autocrine Role of Vascular Endothelial Growth Factor in Squamous Cell Carcinoma
VEGF helps squamous cell carcinoma grow in ways beyond just blood vessel formation.
research Anticancer Drugs in Surface Waters
Anticancer drugs are increasingly found in surface waters, and their long-term environmental effects are not well understood, requiring better testing methods.
research Retinoid-Mediated Stimulation of Steroid Sulfatase Activity in Myeloid Leukemic Cell Lines Requires RARα and RXR and Involves the Phosphoinositide 3-Kinase and ERK-MAP Kinase Pathways
Retinoids increase steroid sulfatase activity in leukemia cells through RARα/RXR and involves certain pathways like phosphoinositide 3-kinase and ERK-MAP kinase.
research Malignant Epithelial Tumors: Part II. Therapy and Prevention
The document concludes that individualized treatment for malignant epithelial tumors is necessary and more research on metastatic squamous cell carcinoma treatments is needed.
research Nilotinib-Induced Generalized Keratosis Pilaris: Report of a Rare Case
Nilotinib can cause generalized keratosis pilaris.
research Severe Scarring Alopecia Associated with Combinational Use of Ficlatuzumab and Gefitinib: A Clinical and Immunohistochemistry Study
Combining ficlatuzumab and gefitinib can cause severe scarring hair loss.
research Erosive Pustular Dermatosis of the Scalp Induced by Gefitinib: Case and Review of the Literature
An 84-year-old man developed a rare scalp condition from a cancer drug but continued treatment as it was otherwise well tolerated.
research Nilotinib-Induced Keratosis Pilaris
Nilotinib can cause keratosis pilaris, a skin condition.
research Immunopathology and Immunotherapy of Inflammatory Skin Diseases
New targeted immunotherapies are improving treatment for inflammatory skin diseases.
research Cutaneous Toxicity as a Predictive Biomarker for Clinical Outcome in Patients Receiving Anticancer Therapy
Skin reactions from cancer treatments might predict how well the treatments work.
research Targeting the Hippo/YAP/TAZ Signalling Pathway: Novel Opportunities for Therapeutic Interventions into Skin Cancers
Blocking YAP/TAZ could be a new way to treat skin cancer.
research Molecular Targeted Agents and Biologic Therapies for Non-Small Cell Lung Cancer
New treatments for non-small cell lung cancer are being tested, with some already in use, focusing on immune response and targeting cancer cells, but side effects vary.
research Protein Degradation: Expanding the Toolbox to Restrain Cancer Drug Resistance
Using protein degradation to fight cancer drug resistance shows promise but needs more precise targeting and fewer side effects.
research Dermatologic Adverse Events Associated With Afatinib: An Oral ErbB Family Blocker
Afatinib often causes skin problems that need proactive management.
research Large-Scale Multicenter Prospective Registry Study of Ripretinib in Advanced GIST: A Real-World Study from China
Ripretinib is effective and safe for treating advanced GIST in Chinese patients, particularly for non-gastric GISTs.
research Molecular Targeted Therapies for Cancer: Sorafenib Monotherapy and Its Combination with Other Therapies
Sorafenib helps some advanced cancers alone or with other treatments, but not all, and research continues to improve its use.
research Skin Toxicity of Anti-Cancer Therapy
Anti-cancer treatments can cause reversible hair loss, skin sensitivity, pigmentation changes, nail damage, and skin reactions, with a need for more research on managing these side effects.
research Spironolactone, a Classic Potassium-Sparing Diuretic, Reduces Survivin Expression and Chemosensitizes Cancer Cells to Non-DNA-Damaging Anticancer Drugs
Spironolactone may make some cancer treatments more effective by blocking a protein that helps cancer cells survive.
research Delayed Onset Perforating Folliculitis Associated with Sorafenib
Sorafenib can cause delayed skin problems, so patients need careful monitoring.
research Warfarin-Induced Alopecia: A Rare Case Report
Warfarin can rarely cause hair loss, which is usually reversible.
research Index
Chemotherapy can cause skin issues and hair loss, and this guide explains how to manage them.
research Kinase Inhibition with BAY 43-9006 in Renal Cell Carcinoma
BAY 43-9006 helps control kidney cancer growth but doesn't significantly increase overall survival.
research Pathobiology of Chemotherapy-Induced Hair Loss
Chemotherapy causes hair loss by damaging hair follicles and stem cells, with more research needed for prevention and treatment.
research Careless Talk Costs Lives: Fibroblast Growth Factor Receptor Signalling and the Consequences of Pathway Malfunction
Fibroblast growth factor receptor signaling controls cell development and repair, and its malfunction can cause disorders and cancer, but it also offers potential for targeted therapies.
research Pathogenesis and Treatment Options for Chemotherapy-Induced Alopecia: A Systematic Review
Scalp cooling is the most effective FDA-approved method to prevent chemotherapy-induced hair loss, but more research is needed for other treatments.
research Ovary And Uterus Related Adverse Events Associated With Statin Use: An Analysis Of The FDA Adverse Event Reporting System
Statins may be linked to reproductive organ conditions, and their risks should be monitored.
research Effects of Adenosine Triphosphate on Vandetanib-Induced Skin Damage in Rats
ATP helps prevent skin damage from vandetanib by reducing stress.
research Vandetanib-Associated Alopecia Areata in a Patient with Metastatic Medullary Thyroid Cancer
A cancer patient developed a type of hair loss after starting a cancer drug called vandetanib.